|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al CONCORD Working Group, : Global surveillance of
trends in cancer survival 2000-14 (CONCORD-3): Analysis of
individual records for 37 513 025 patients diagnosed with one of 18
cancers from 322 population-based registries in 71 countries.
Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang L, Parkin DM, Li LD, Chen YD and Bray
F: Estimation and projection of the national profile of cancer
mortality in China: 1991-2005. Br J Cancer. 90:2157–2166. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kulik L, Heimbach JK, Zaiem F, Almasri J,
Prokop LJ, Wang Z, Murad MH and Mohammed K: Therapies for patients
with hepatocellular carcinoma awaiting liver transplantation: A
systematic review and meta-analysis. Hepatology. 67:381–400. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khut PY, Tucker B, Lardelli M and Wood SA:
Evolutionary and expression analysis of the zebrafish
deubiquitylating enzyme, usp9. Zebrafish. 4:95–101. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pérez-Mancera PA, Rust AG, van der Weyden
L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R,
Aust D, Rümmele P, et al Australian Pancreatic Cancer Genome
Initiative, : The deubiquitinase USP9X suppresses pancreatic ductal
adenocarcinoma. Nature. 486:266–270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kapuria V, Peterson LF, Fang D, Bornmann
WG, Talpaz M and Donato NJ: Deubiquitinase inhibition by
small-molecule WP1130 triggers aggresome formation and tumor cell
apoptosis. Cancer Res. 70:9265–9276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kerscher O, Felberbaum R and Hochstrasser
M: Modification of proteins by ubiquitin and ubiquitin-like
proteins. Annu Rev Cell Dev Biol. 22:159–180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Liu Y, Yang B, Cao H, Yang CX,
Ouyang W, Zhang SM, Yang GF, Zhou FX, Zhou YF, et al: Elevated
expression of USP9X correlates with poor prognosis in human
non-small cell lung cancer. J Thorac Dis. 7:672–679.
2015.PubMed/NCBI
|
|
11
|
Peng J, Hu Q, Liu W, He X, Cui L, Chen X,
Yang M, Liu H, Wei W, Liu S, et al: USP9X expression correlates
with tumor progression and poor prognosis in esophageal squamous
cell carcinoma. Diagn Pathol. 8:1772013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bernassola F, Karin M, Ciechanover A and
Melino G: The HECT family of E3 ubiquitin ligases: Multiple players
in cancer development. Cancer Cell. 14:10–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing
T, Dong L, Tang E and Yang H: Over-expression of genes and proteins
of ubiquitin specific peptidases (USPs) and proteasome subunits
(PSs) in breast cancer tissue observed by the methods of RFDD-PCR
and proteomics. Breast Cancer Res Treat. 104:21–30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rolén U, Kobzeva V, Gasparjan N, Ovaa H,
Winberg G, Kisseljov F and Masucci MG: Activity profiling of
deubiquitinating enzymes in cervical carcinoma biopsies and cell
lines. Mol Carcinog. 45:260–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burger AM and Seth AK: The
ubiquitin-mediated protein degradation pathway in cancer:
Therapeutic implications. Eur J Cancer. 40:2217–2229. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pardali K and Moustakas A: Actions of
TGF-β as tumor suppressor and pro-metastatic factor in human
cancer. Biochim Biophys Acta. 1775:21–62. 2007.PubMed/NCBI
|
|
17
|
Hu H, Tang C, Jiang Q, Luo W, Liu J, Wei
X, Liu R and Wu Z: Reduced ubiquitin-specific protease 9X
expression induced by RNA interference inhibits the bioactivity of
hepatocellular carcinoma cells. Oncol Lett. 10:268–272. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu F, Zhao X, Perna F, Wang L, Koppikar
P, Abdel-Wahab O, Harr MW, Levine RL, Xu H, Tefferi A, et al:
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its
methyltransferase activity and promotes myeloproliferation. Cancer
Cell. 19:283–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu JH, Kim KH and Kim H: SOCS 3 and PPAR-γ
ligands inhibit the expression of IL-6 and TGF-β1 by regulating
JAK2/STAT3 signaling in pancreas. Int J Biochem Cell Biol.
40:677–688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Griffiths DS, Li J, Dawson MA, Trotter MW,
Cheng YH, Smith AM, Mansfield W, Liu P, Kouzarides T, Nichols J, et
al: LIF-independent JAK signalling to chromatin in embryonic stem
cells uncovered from an adult stem cell disease. Nat Cell Biol.
13:13–21. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berishaj M, Gao SP, Ahmed S, Leslie K,
Al-Ahmadie H, Gerald WL, Bornmann W and Bromberg JF: Stat3 is
tyrosine-phosphorylated through the interleukin-6/glycoprotein
130/Janus kinase pathway in breast cancer. Breast Cancer Res.
9:R322007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu R, Liu Y, Zhao Y, Bi Z, Yao Y, Liu Q,
Wang F, Wang Y and Wang X: m6A methylation controls pluripotency of
porcine induced pluripotent stem cells by targeting
SOCS3/JAK2/STAT3 pathway in a YTHDF1/YTHDF2-orchestrated manner.
Cell Death Dis. 10:1712019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kong E, Sucic S, Monje FJ, Savalli G, Diao
W, Khan D, Ronovsky M, Cabatic M, Koban F, Freissmuth M, et al:
STAT3 controls IL6-dependent regulation of serotonin transporter
function and depression-like behavior. Sci Rep. 5:90092015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chua CY, Liu Y, Granberg KJ, Hu L,
Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller
GN, et al: IGFBP2 potentiates nuclear EGFR-STAT3 signaling.
Oncogene. 35:738–747. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hansen MF, Greibe E, Skovbjerg S, Rohde S,
Kristensen AC, Jensen TR, Stentoft C, Kjær KH, Kronborg CS and
Martensen PM: Folic acid mediates activation of the pro-oncogene
STAT3 via the Folate Receptor alpha. Cell Signal. 27:1356–1368.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shirogane T, Fukada T, Muller JMM, Shima
DT, Hibi M and Hirano T: Synergistic roles for Pim-1 and c-Myc in
STAT3-mediated cell cycle progression and antiapoptosis. Immunity.
11:709–719. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kasza A: Signal-dependent Elk-1 target
genes involved in transcript processing and cell migration. Biochim
Biophys Acta. 1829:1026–1033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ou Y, Liu L, Xue L, Zhou W, Zhao Z, Xu B,
Song Y and Zhan Q: TRAP1 shows clinical significance and promotes
cellular migration and invasion through STAT3/MMP2 pathway in human
esophageal squamous cell cancer. J Genet Genomics. 41:529–537.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feng J, Yu SY, Li CZ, Li ZY and Zhang YZ:
Integrative proteomics and transcriptomics revealed that activation
of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with
invasion of pituitary null cell adenomas. Mol Cell Endocrinol.
436:195–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Huo X, Yang XR, He J, Cheng L,
Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated
upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer
metastasis by regulating SOX4. Mol Cancer. 16:1362017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu B, Zhang K, Li S, Li H, Yan Z, Huang L,
Wu J, Han X, Jiang W, Mulatibieke T, et al: HIC1 attenuates
invasion and metastasis by inhibiting the IL-6/STAT3 signalling
pathway in human pancreatic cancer. Cancer Lett. 376:387–398. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao K, Gong H, Qiu Z, Wen Q, Zhang B, Tang
T, Zhou X, Cao T, Wang B, Shi H, et al: Hepatitis B virus X protein
reduces the stability of Nrdp1 to up-regulate ErbB3 in
hepatocellular carcinoma cells. Tumour Biol. 37:10375–10382. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang J, Zheng C and Shao J, Chen L, Liu X
and Shao J: Overexpression of eEF1A1 regulates G1-phase progression
to promote HCC proliferation through the STAT1-cyclin D1 pathway.
Biochem Biophys Res Commun. 494:542–549. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang C, Yao B, Xu M and Zheng X: RIP1
upregulation promoted tumor progression by activating AKT/Bcl-2/BAX
signaling and predicted poor postsurgical prognosis in HCC. Tumour
Biol. 37:15305–15313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xia W, Zhuang J, Wang G, Ni J, Wang J and
Ye Y: P4HB promotes HCC tumorigenesis through downregulation of
GRP78 and subsequent upregulation of epithelial-to-mesenchymal
transition. Oncotarget. 8:8512–8521. 2017. View Article : Google Scholar : PubMed/NCBI
|
